Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports

BACKGROUND: Many scientists across the world got involved in the race to develop successful anti-SARS-CoV-2 vaccines to overcome COVID-19 pandemic. Among the different vaccines developed against SARS-CoV-2, Covishield was the first vaccine approved for emergency use in Nepal. We report two cases of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sah, Mukesh Kumar, Singh, Bishnu Mohan, Sinha, Puja, Devkota, Prerit, Yadav, Sudhira Kumari, Shrestha, John, Shrestha, Ashis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076162/
https://www.ncbi.nlm.nih.gov/pubmed/35524323
http://dx.doi.org/10.1186/s13256-022-03407-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076162/
https://www.ncbi.nlm.nih.gov/pubmed/35524323
http://dx.doi.org/10.1186/s13256-022-03407-6

Ejemplares similares